Akademia Medyczna

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper published in 'Allergy' DAVOS, Switzerland, Oct. 10, 2023 /PRNewswire/ -- The revision of the current allergic disease nomenclature based on symptoms and organ dysfunction has been long-awaited at the time of modern patient-tailored treatments and precision medicine. The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management. EAACI is the world leader in allergy science and education. The world's key opinion leaders gathered around the initiative of the European Academy of Allergy and Clinical Immunology (EAACI) to present a new classification of allergic disorders based on the mechanisms of diseases. Published online today in Allergy, the position paper reveals the new way allergic diseases are perceived. We expect the new classification to profoundly change the healthcare professionals' approach to managing allergic diseases since it provides key solutions to a personalised approach . It is focused on the roles of immune-competent cells, changes in the tissues, the role of microbial infections, and genetic and epigenetic influences, all affecting the protective epithelial barrier of the skin, respiratory tract and gut. The exponential growth of precision diagnostic tools, including omic technology, molecular diagnostics, imaging, sophisticated genetic and epigenetic editing, nano-technologies, etc., compels us to introduce a more nuanced concept, moving the field towards precision and personalised medicine. The general consensus and fast dissemination of the new nomenclature of allergic diseases are crucial to developing the entire field of management of immune-mediated diseases. The cultural change brought by the new nomenclature will lead to novel concepts of diagnostic tools, improving therapies, and disease management and will guide future research into more innovative strategies for patient care. This will include new pinpoint targeted immune-based therapies, especially with substances made from living organisms, called biologicals, allergen immunotherapy, as well as strategies to alter the composition of the microbiome in humans among many others. The value of an idea lies in the use of it. We hope that the new nomenclature for allergic diseases developed by EAACI will help healthcare professionals and patients find a better way to manage and even cure allergic diseases. Contact: Prof. Marek Jutel MD, Head of the Department of Clinical Immunology, Wroclaw Medical University, Poland. [email protected], phone +48 71 784 17 40 Prof. Ioana Agache MD, Faculty of Medicine, Transylvania University, Brasov, Romania. [email protected], phone +40 727 849 321 Prof. Dr. Cezmi A. Akdis, Director, Swiss Institute of Allergy and Asthma Research, Davos, Switzerland. [email protected], phone: ++41 78 738 82 84 Direct link to download free access article: SOURCE SIAF

HAMBURG, Germany, June 11, 2023 /PRNewswire/ -- A study conducted by researchers from the ALL-MED Medical Research Institute and the Department of Clinical Immunology at Wroclaw Medical University in Poland has validated the use of an allergen exposure chamber (AEC) in assessing the clinical outcomes of house dust mite (HDM) allergen immunotherapy (AIT) in patients with allergic rhinoconjunctivitis. The study focused on evaluating the efficacy and safety of AEC-derived clinical outcomes of subcutaneous HDM AIT, a treatment designed to alleviate symptoms triggered by HDM allergies. Fifty patients with HDM-triggered allergic rhinoconjunctivitis were included in the study, with HDM allergy confirmed through various diagnostic tests such as skin prick tests, serum-specific IgE, and basophil activation tests. During the study, patients were assessed in the allergen exposure chamber before commencing AIT and after 12 months of treatment. The chamber provided a controlled environment, allowing patients to be exposed to HDM allergen under stable and well-regulated conditions. Various clinical endpoints, including total nasal symptom score (TNSS), visual analog scale (VAS), and objective parameters such as acoustic rhinometry, peak nasal inspiratory flow (PNIF), and nasal secretion weight, were used to assess the effectiveness of AIT. The results of the study demonstrated a statistically significant reduction in TNSS (p<0.005) after one year of AIT, indicating the positive impact of the treatment on nasal symptoms. There was a high reduction in nasal symptoms observed using other objective parameters (PNIF, nasal secretion, acoustic rhinometry-MCA). These findings suggest the potential of AEC as a valuable tool for data collection, proof-of-concept studies, and biomarker analysis. "The study findings demonstrate that the Allergen Exposure Chamber (AEC) challenge is consistent and safe, allowing researchers to collect data quickly and of high quality. Moreover, the results indicate that the clinical measurements obtained in the AEC align well with the effectiveness evaluation using the Combined Symptom and Medication Score (CSMS) in real-life conditions. This suggests that the AEC could serve as an alternative to traditional trial designs. Specifically, the Total Nasal Symptom Score (TNSS) measured in the AEC is identified as a reliable primary endpoint in clinical trials. However, nasal provocation tests (NPT) may not be suitable as a primary endpoint since they do not correlate well with CSMS in real-life conditions and TNSS in the AEC", says Professor Marek Jutel from Wroclaw. The researchers emphasize the importance of further validating clinical endpoints using immunological biomarkers for the continued development and application of AEC in clinical trials. The study also suggests that accelerated dose escalation of native HDM AIT is both safe and convenient. A movie on Allergen Chamber test is available here: In conclusion, the study confirms that the allergen exposure chamber challenge is an effective, reproducible, and safe method for assessing the outcomes of HDM AIT in patients with allergic rhinoconjunctivitis. Ongoing research is being conducted to validate clinical endpoints using immunological biomarkers, offering promising prospects for improved diagnostic and treatment approaches. About EAACI: The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 15 000 members from 125 countries and over 75 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. Contact: EAACI Headquarters, Hagenholzstrasse 111, 3rd Floor 8050 Zurich, CH- Switzerland Tel: +41799561865 [email protected] Logo: SOURCE EAACI

First commercial implantations of the HAART 200 Device for Bicuspid Aortic Valve repair performed by Professor Marek Jasinski at the Wroclaw Medical University BioStable Science & Engineering Initiates European Commercialisation of the HAART 200 Aortic Annuloplasty Device. (Credit: Raman Oza from Pixabay) BioStable Science & Engineering, Inc. announced today that the first commercial implantations of its HAART 200 Aortic Annuloplasty Device were performed on Monday, August 2nd by Professor Marek Jasinski, Chief of Cardiac Surgery at Wroclaw Medical University (Wroclaw, Poland). Additional procedures were completed on Thursday, August 5th by Professor Marek Deja, Chief of Cardiac Surgery at the Medical University of Silesia (Katowice, Poland). These two respected heart centers were the first selected to receive the HAART 200 Aortic Annuloplasty Device as part of the limited European commercial launch of the technology announced by the company in April. Professor Jasinski commented, “The HAART 200 Aortic Annuloplasty Device is a great addition to our aortic valve repair tool kit providing a new option for the most common congenital heart defect, bicuspid aortic valve disease. Our experience with the HAART 300 Aortic Annuloplasty Devices in trileaflet aortic valve repair has shown us how the devices simplify aortic valve repair and at the same time provide durable annuloplasty. This allows us to expand the benefits of valve repair to more patients. The availability of the HAART 200 Device is critically important because patients with bicuspid aortic valve disease are younger, multiplying the benefits of valve repair vs. replacement.” Although compelling long-term clinical data suggest that almost all bicuspid aortic valves should be repaired[1], current repair techniques are complex and not widely adopted. The HAART 200 Device simplifies bicuspid aortic valve repair by stabilizing the annulus and remodeling the valve into a symmetric, 180-degree leaflet orientation, eliminating the need for extensive dissection of the aortic root, and facilitating leaflet repair. John Wheeler, President and CEO, concluded by saying, “BioStable is very pleased to initiate commercialization of the HAART 200 Aortic Annuloplasty Device alongside the HAART 300 Devices. With the commercial availability of the HAART 200 and HAART 300 Aortic Annuloplasty Devices, BioStable can offer surgeons within the European a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency.” Source: Company Press Release